Skip to main content
NIH funding notice RFA-HL-26-018

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

Open. Closes December 23, 2027.

Posted
November 22, 2024
Close date
December 23, 2027
Activity codes
R33
Institutes taking part
NHLBI, NIAID

The notices it replaced

2 notices since 2019, oldest first, each with its awards since FY2014.

  1. Posted 2019RFA-HL-20-0276 awards
  2. Posted 2022RFA-HL-23-0124 awards
  3. Posted 2024RFA-HL-26-018This notice, open · 1 award

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
11
10 new, 1 renewal
Median first-year cost
$561,030
$6,192,711 in all
Institutions
11
11 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. BOSTON CHILDREN'S HOSPITAL1
  2. BRIGHAM AND WOMEN'S HOSPITAL1
  3. CHILDREN'S RESEARCH INSTITUTE1
  4. INDIANA UNIVERSITY INDIANAPOLIS1
  5. MASSACHUSETTS GENERAL HOSPITAL1

and 6 other institutions

Most frequent study sections

  1. Special Emphasis Panel (ZHL1 CSR-R (M1))3
  2. Special Emphasis Panel (ZHL1 CSR-F (M1))2
  3. Special Emphasis Panel (ZHL1 CSR-F (O1))2
  4. Special Emphasis Panel (ZHL1 CSR-E (O1))1
  5. Special Emphasis Panel (ZHL1 CSR-F (J1))1

and 2 other study sections

11 awards under RFA-HL-26-018 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2026A New Lipid Nanoparticle Technology Enabling Long-Acting mRNA Therapy2R33HL168751-03Shi, JinjunBRIGHAM AND WOMEN'S HOSPITAL, MAFirst-year cost $726,905Study section ZRG1
FY2025Immunocytokine therapy for immune modulation in hemophilia1R33HL177497-01 · under RFA-HL-23-012Biswas, MoanaroINDIANA UNIVERSITY INDIANAPOLIS, INFirst-year cost $582,638Study section ZHL1
FY2024Enhancing efficacy of virus-specific T cell therapy following hematopoietic stem cell transplantation by CD52 knockout1R33HL175692-01 · under RFA-HL-23-012Keller, Michael DanielCHILDREN'S RESEARCH INSTITUTE, DCFirst-year cost $561,030Study section ZHL1
FY2024RNA-based therapeutics for hemostasis and thrombosis1R33HL173910-01 · under RFA-HL-23-012Goldfinger, Lawrence EStalker, Timothy J.THOMAS JEFFERSON UNIVERSITY, PAFirst-year cost $546,000Study section ZHL1
FY2024Peptides for the treatment of pulmonary fibrosis1R33HL175682-01 · under RFA-HL-23-012Feghali-Bostwick, Carol A.MEDICAL UNIVERSITY OF SOUTH CAROLINA, SCFirst-year cost $464,121Study section ZHL1
FY2022Developing a Novel E3 Ligase based Anti-inflammatory for ARDS1R33HL157877-01A1 · under RFA-HL-20-027Mallampalli, Rama KOHIO STATE UNIVERSITY, OHFirst-year cost $551,250Study section ZHL1
FY2022Optimization of small molecule integrin activators to enhance cord blood transplant1R33HL161778-01 · under RFA-HL-20-027Biediger, Ronald JVanderslice, PeterTEXAS HEART INSTITUTE, TXFirst-year cost $547,028Study section ZHL1
FY2021Ultrasound-mediated thrombolysis for MVO and PAO treatment.1R33HL156350-01 · under RFA-HL-20-027Meuillet, Emmanuelle JoellePacella, John JMICROVASCULAR THERAPEUTICS, LLC, AZFirst-year cost $575,012Study section ZHL1
FY2020Novel small molecules to treat degenerative lung and blood diseases1R33HL154133-01 · under RFA-HL-20-027Agarwal, SuneetBOSTON CHILDREN'S HOSPITAL, MAFirst-year cost $619,500Study section ZHL1
FY2020Optimization of PET probe for imaging lung fibrogenesis1R33HL154125-01 · under RFA-HL-20-027Caravan, Peter DMASSACHUSETTS GENERAL HOSPITAL, MAFirst-year cost $588,000Study section ZHL1
FY2020Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension1R33HL154135-01 · under RFA-HL-20-027Singh, JaipalVASCULONICS, LLC, INFirst-year cost $431,227Study section ZHL1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-16-0.3.5. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-HL-26-018: Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) | ScienceDex | ConductScience